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dAristotleIn only the past few years, we have witnessed innovations in
percutaneous coronary intervention and noninvasive imaging
that promise to “disrupt” the treatment and diagnosis of
coronary artery disease (CAD). At ﬁrst glance, these tech-
nologies appear disconnected from one another, with little
overlap for clinical use. Yet, as Onuma et al. (2) describe in an
elegant study published in this issue of JACC: Cardiovascular
Interventions, these technologies, when combined, hold the
potential to encourage a new clinical paradigm that may
enhance the treatment and follow-up of patients withCAD in
a safe, clinically effective, and economically efﬁcient manner.
See page 999
As the fourth in the generation of percutaneous coronary
stents, bioabsorbable drug-eluting vascular scaffolds (BVS)
have emerged as an effective platform that rivals, if not
exceeds, prior drug-eluting stents for safety and efﬁcacy. As
1 example, the fully resorbable everolimus-eluting Absorb
BVS, the particular stent evaluated in the present study,
couples an antiproliferative kinase inhibitor with a scaffold
composed of poly-L-lactide (PLLA) and poly-D,L-lactide
(PDLLA), both of which are naturally metabolized by the
body via the Krebs cycle to water and carbon dioxide (3).
The rationale behind this type of stent is obvious, and early
studies have substantiated the safety of BVS stents, with no
observed stent thromboses and with major adverse cardio-
vascular event rates that are comparable to those seen withublished in JACC: Cardiovascular Interventions reﬂect the views of the
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118019).latest generation drug-eluting stents (4). In the study by
Onuma et al. (2), long-term ischemia-driven major adverse
cardiovascular events after Absorb BVS implantation were
evaluated and occurred at an incidence of 3.4% at 5 years,
which was unchanged from the 1-year and 2-year follow-up
studies. Given the bioabsorbable design, these scaffolds
demonstrate lucency by both invasive (angiography and
optical coherence tomography) and noninvasive (coronary
computed tomographic angiography [CCTA]) imaging.
The latter of these techniques has also witnessed numerous
technological advancements. Since the introduction of 64–
detector row CCTA in 2005, several multicenter trials have
established the high diagnostic performance ofCCTA,which,
when compared with a quantitative angiographic reference
standard, exhibits an ability to identify and exclude anatomi-
cally obstructive CAD in a manner superior to that of other
noninvasive tests (5). Importantly, for patients without known
CAD, the negative predictive value to exclude obstructive
CAD in native coronary arteries approaches 100%.
Despite this, for patients with knownCAD, particularly for
those with prior metallic stent implantation, the diagnostic
performance of CCTA is generally poor, with a high rate of
nonevaluable stents. The primary diagnostic challenge of
CCTA for stents, particularly smaller stents, is related to
partial volume effects, a phenomenon that relates to the limited
spatial resolution of current-generation CCTA. Because of
these limitations, aside from evaluation of left main stents
3 mm in diameter, the most current American College of
Cardiology appropriate use criteria consider the use of CCTA
for the evaluation of metallic stents as inappropriate (6). This
contrasts starkly with 35 clinical indications for which CCTA
for native coronary arteries is considered appropriate.
Yet even with improved resolution, CCTA alone does not
provide physiologic information such as that enabled by
invasive fractional ﬂow reserve (FFR), thus precluding its
ability to identify stenoses that reduce coronary ﬂow and
pressure. Recently, however, FFR derived from CCTA
(FFRCT) has emerged an adjunctive test to CCTA for the
diagnosis of hemodynamically signiﬁcant coronary stenoses.
In 2 prospective multicenter studies, FFRCT compared
favorably with invasive FFR (7,8). Advantageously, FFRCT
can be performed on any typically acquired CCTA, thus
negating the need for additional imaging, administration
of medications, or added radiation dose. In addition, given
the entire patient-speciﬁc arterial geometry provided by
CCTA segmentation, an FFR value can be calculated at any
point in the coronary vascular bed, thus delivering a compre-
hensive “3-vessel” FFR from a single noninvasive test.
The study by Onuma et al. (2) combines these seemingly
disparate therapeutic and diagnostic technologies to evaluate
the feasibility of a new clinical paradigm: implantation of
a BVS stent with follow-up evaluation by CCTA and
FFRCT. Given the lucency enabled by resorption of PLLA
and PDLLA in the Absorb BVS stents, initial images from
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1011CCTA of BVS appear strikingly similar to those of native
coronary arteries. In the present study, CCTAwas evaluable in
18 of 18 patients, with quantitative measures of minimal
luminal area, and FFRCT was feasible in 13 of 18 patients
who underwent CCTA. These are important ﬁndings and
have potentially large ramiﬁcations, given the common occur-
rence of patients’ presenting with symptoms after stent place-
ment and the frequent need for invasive and costly testing.
In this regard, the study by Onuma et al. (2) raises 2
important noninvasive possibilities. First, aside from radi-
opaque platinum markers at the ends of the Absorb BVS
stent, the stented coronary artery segments appear indis-
tinguishable from native coronary artery segments, thus
raising the possibility that CCTA may rule out in-stent
restenosis in these segments with the near 100% accuracy
that is observed for native coronary arteries. Second, even
among those identiﬁed with in-stent restenosis, the con-
comitant use of FFRCT raises the opportunity to evaluate
the physiologic signiﬁcance of any identiﬁed lesion.
Given the small study sample of the present investigation,
these goals couldnot be fully evaluatedbut rather are presented as
a “proof-of-principle” study. This feasibility study allowed the
performance of CCTA at sites to be dictated by local site prac-
tices rather than by guideline-based methods but did required
pre-study site certiﬁcation to demonstrate the quality of CCTA.
Furthermore, blinded independent core laboratories provided
interpretation of both CCTA as well as FFRCT, thus rendering
this a diagnostic efﬁcacy rather than effectiveness study.
Thus, although exciting as a novel clinical paradigm for
the treatment of patients receiving Absorb BVS stents with
follow-up by CCTA and FFRCT, numerous questions be-
yond those already raised remain that require answers be-
fore this approach can be widely adopted. Perhaps most
important, this study evaluated only single stents 3 mm in
diameter for simple anatomic lesions, and the feasibility of
CCTA for Absorb BVS stents <3 mm remains in need of
further investigation. Also, although each of the patients in
this small study could be evaluated by CCTA, more than
one-fourth could not be evaluated by FFRCT. Future larger
studies determining the rate of well-performed CCTA than
canbe evaluated byFFRCT in this population appear needed.A
prospectivemulticenter European FFRCT trial is ongoing, and
with enrollment completed, these study resultsmay inform this
question. Furthermore, although the present study examined
the long-term appearance of the Absorb BVS stent, the use of
CCTA in the near-term period after implantation is still in
question. PLLAandPDLLAfully absorb by 9 and36months,
respectively, and clinical data regarding the appearance on
CCTA of the Absorb BVS over time are not yet fully available.
In addition, although the initial appearance of theAbsorb BVS
on CCTA appears to replicate that of native coronary arteries,
whether the diagnostic performance of CCTA for BVS stents
is superior to traditional metallic stents remains unknown.
Head-to-head comparison studies are nowneeded. Finally, theuse of Absorb BVS followed by use of noninvasive testing
for the evaluation of patients with suspected in-stent restenosis
seems is intuitively safer and more economically efﬁcient,
but cost-effectiveness studies are now indicated.
In sum, Onuma et al. (2) should be commended for
combining the use of seemingly disparate invasive and
noninvasive technologies into a single common clinical
paradigm. Although only a feasibility investigation, their
study results raise hope for a safer method of treatment and
follow-up for patients with CAD who require percutaneous
interventions. By uniting these different methods into
a single clinical pathway, they have taken the ﬁrst step
toward substantiating Aristotle’s claim that the whole is
greater than the sum of its parts.
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